Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review/meta-analysis. ^[1]
• Odevixibat (Bylvay) significantly reduced itch scores by 1.8 points on the Itch Reported Outcome (ItchRO) scale and decreased serum bile acids by 75.8 µmol/L in patients with Alagille syndrome (ALGS). Additionally, pediatric quality of life scores improved by 8.3 points, and fatigue, measured by the Multidimensional Fatigue Scale, improved by 11.4 points.
• Both odevixibat and maralixibat demonstrated effectiveness in reducing pruritus and serum bile acids in ALGS patients. However, no specific comparative figures between these two drugs were detailed in the study. The findings focus on improvements in quality of life, itch, and biochemical markers for the ALGS population.
• Odevixibat (Bylvay) treatment was associated with an increase in alanine aminotransferase (ALT) levels by 40 U/L, indicating potential liver stress or damage, requiring close monitoring in patients.
• Gastrointestinal side effects were noted, although specific details on their frequency or nature were not provided, suggesting a need for future trials to evaluate their impact on treatment and dosing regimens.
• The study population consisted of patients with Alagille syndrome (ALGS), a rare genetic condition characterized by chronic cholestasis and refractory pruritus. No specific population subgroups (e.g., age groups, gender, or comorbidities) were reported, and findings on effectiveness and safety apply generally to the entire ALGS patient population studied.